anapen 300 mikrogram/0,3 ml injektionsvæske, opløsning
bioprojet pharma - adrenalin - injektionsvæske, opløsning - 300 mikrogram/0,3 ml
anapen junior 150 mikrogram/0,3 ml injektionsvæske, opløsning
bioprojet pharma - adrenalin - injektionsvæske, opløsning - 150 mikrogram/0,3 ml
biocom p vet. injektionsvæske, suspension
united vaccines holding bv - clostridium botulinum type c, toxoid, mink enteritis virus inaktiveret, pseudomonas aeruginosa habs serotype 5 (inaktiveret), pseudomonas aeruginosa habs serotype 6 (inaktiveret), pseudomonas aeruginosa habs serotype 7-8 (inaktiveret) - injektionsvæske, suspension - pelsdyr (f.eks. mink)
tafen nasal 32 mikrogram/dosis næsespray, suspension
orifarm a/s - budesonid - næsespray, suspension - 32 mikrogram/dosis
xylocain-adrenalin 10 mg/ml+5 mikrog/ml injektionsvæske, opløsning
aspen pharma trading limited - adrenalintartrat, lidocainhydrochlorid, vandfrit - injektionsvæske, opløsning - 10 mg/ml+5 mikrog/ml
xyloplyin dental adrenalin 20 mg+12,5 mikrog/ml injektionsvæske, opløsning
dentsply detrey gmbh - adrenalintartrat, lidocainhydrochlorid - injektionsvæske, opløsning - 20 mg+12,5 mikrog/ml
xyloplyin dental adrenalin 20 mg+12,5 mikrog/ml injektionsvæske, opløsning
orifarm a/s - adrenalintartrat, lidocainhydrochlorid - injektionsvæske, opløsning - 20 mg+12,5 mikrog/ml
febrivac pbe vet. injektionsvæske, suspension
idt biologika gmbh - clostridium botulinum type c, stamme stockholm, toxoid, mink parvovirus, stamme e-mink f1 (inaktiveret), pseudomonas aeruginosa habs serotype 5 (inaktiveret), pseudomonas aeruginosa habs serotype 6 (inaktiveret), pseudomonas aeruginosa habs serotype 7-8 (inaktiveret) - injektionsvæske, suspension - pelsdyr (f.eks. mink)
rayaldee 30 mikrogram depotkapsler, bløde
vifor fresenius medical care renal pharma france - calcifediol - depotkapsler, bløde - 30 mikrogram
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svin - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.